Migraine and Women's Health: Migraine and the Whole Female Patient

Migraine and Women's Health: Migraine and the Whole Female Patient

ReachMD Healthcare Image
RestartResume

Migraine is the second-most disabling disease globally and the most disabling for women 14-59. New effective agents are available. Are you prepared?

Available credits: 0.75

Time to complete: 45 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Upwards of 47 million people in the U.S. suffer from migraines, often accompanied by widespread personal, professional, and social disabilities. Though a similar prevalence is initially observed between men and women, by mid-adulthood the prevalence of migraine is 3-fold greater in women than men. Newer agents, both injectable and oral and focused on modulating the calcitonin gene-related peptide pathway, have emerged and have proven highly effective in managing both acute and chronic migraine. Join Drs. Jessica Ailani and Dawn Buse as they provide an overview of the changing landscape of migraine therapy, especially as it impacts women across different life-stages.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Jessica Ailani, MD
    Director, Georgetown Headache Center
    Medstar Georgetown University Hospital
    Washington, DC

    Research: Ipsen, Parema, Satsuma
    Consulting Fees: Abbvie, Aeon, Amgen, Axsome, Biohaven, GlaxoSmithKline, Gore, Impel, Ipsen, Lilly, Lundbeck, Merz, Miravo, Neurolief, Pfizer, Satsuma, Teva, Theranica

    Faculty:
    Dawn C. Buse, PhD
    Clinical Professor
    Albert Einstein College of Medicine
    Bronx, NY

    Consulting Fees: Allergan/AbbVie, Amgen, Biohaven, Collegium, Lilly, Lundbeck, Teva, Theranica

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, Ph.D. has nothing to disclose.
    • Samantha Keehn has nothing to disclose.
    • Brian McDonough, MD has nothing to disclose.
    • Tim Person has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the prevalence and burdens of migraine with especial focus on women.
    • Describe the changing landscape of therapeutic approaches to the treatment of migraine.
    • Discuss data supporting a central role for modulators of the neuropeptide calcitonin gene-related peptide (CGRP) pathway in the management of migraine.
    • Identify personalized evidence-based management strategies for migraine based on the special needs of women.
  • Target Audience

    This activity is designed to meet the educational needs of OBGYN’s, Nurse Practitioners, Physician Associates, and Nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until December 5, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) designates this activity for 0.075 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-23-081-H01-P . This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)


    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from AbbVie and Pfizer, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free